The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.
April 15th 2025
A new review finds federally qualified health centers (FQHCs) are underutilized in hypertension and type 2 diabetes clinical research, despite their potential to improve trial diversity.
Outlook Changing in Payer Coverage for Obesity Medications, Commentators Say
September 25th 2015Many hoped the 2013 declaration by the American Medical Association that obesity is a disease would open the door for payer coverage of pharmacotherapy to treat it. While that did not happen right way, a new commentary in Evidence-Based Diabetes Management by Ted Kyle, RPh, MBA, and Fatima Cody Stanford, MD, MPH, MPA, outlines how the tide appears to be turning for coverage of evidence-based treatment.
Read More
Dissecting the Patient Perception of FDA's Breakthrough Designation
September 23rd 2015A JAMA Internal Medicine study found the terms "breakthrough" and "promising" raised people's expectations on the drug's performance as opposed to when the drugs were described as having met the breakthrough criteria.
Read More
Clinton Seeks Cap on Drug Expenses, Would Let Medicare Negotiate
September 23rd 2015Hillary Clinton unveiled a plan in Iowa that features a $250 per month cap on drug costs for patients with chronic conditions. This comes 2 weeks after her chief rival for the Democratic nomination, US Senator Bernie Sanders of Vermont, introduced a bill aimed at reining in drug costs. In the summer, The American Journal of Managed Care said polling showed that rising drug costs were poised to become a major issue in the 2016 campaign.
Read More
Dr Andrew Pumerantz Reflects on the Role of Primary Care in Diabetes
September 21st 2015Although primary care is important, it may not be the center of the care model for patients with chronic diseases, like type 2 diabetes, and these providers are usually just a part of a larger ecosystem of providers, said Andrew Pumerantz, DO, FACP.
Watch
Stumbling Toward Access to Evidence-Based Care for the Chronic Disease of Obesity
September 18th 2015Many hoped the 2013 declaration by the American Medical Association that obesity is a disease would open the door to improved coverage for pharmcotherapy. That did not happen right away, but signs of change are emerging.
Read More
Empagliflozin Shown to Cut Mortality Risk in Long-Term CV Outcomes Trial
September 17th 2015Presentation of results at the European Association for the Study of Diabetes follows the announcement of topline results in August. For years, researchers and pharmaceutical leaders alike wondered if a diabetes therapy would be shown to have a cardioprotective effect.
Read More